Mutated Toll-like receptor 9 increases Alzheimer's disease risk by compromising innate immunity protection.

[1]  Nick C Fox,et al.  New insights into the genetic etiology of Alzheimer’s disease and related dementias , 2022, Nature Genetics.

[2]  W. Brück,et al.  Analyzing microglial phenotypes across neuropathologies: a practical guide , 2021, Acta Neuropathologica.

[3]  M. Heneka,et al.  Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus , 2021, Nature Reviews Neurology.

[4]  T. Wisniewski,et al.  Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys. , 2021, Brain : a journal of neurology.

[5]  D. Malhotra,et al.  Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory States and Immunosuppression , 2020, Cell reports.

[6]  N. Brandon,et al.  Axl receptor tyrosine kinase is a regulator of apolipoprotein E , 2020, Molecular Brain.

[7]  T. Wisniewski,et al.  Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey (Saimiri Boliviensis Boliviensis) , 2020, Frontiers in Aging Neuroscience.

[8]  Nicholas E. Propson,et al.  PSEN1ΔE9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia , 2019, Stem cell reports.

[9]  Noa Sher,et al.  IFN-β is a macrophage-derived effector cytokine facilitating the resolution of bacterial inflammation , 2019, Nature Communications.

[10]  D. Green,et al.  LC3-Associated Endocytosis Facilitates β-Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer’s Disease , 2019, Cell.

[11]  K. Sleegers,et al.  Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability , 2019, Acta Neuropathologica.

[12]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[13]  G. Forloni,et al.  Exome sequencing in an Italian family with Alzheimer’s disease points to a role for seizure-related gene 6 (SEZ6) rare variant R615H , 2018, Alzheimer's Research & Therapy.

[14]  Toshiyuki Shimizu,et al.  Toll‐like Receptor 9 Contains Two DNA Binding Sites that Function Cooperatively to Promote Receptor Dimerization and Activation , 2018, Immunity.

[15]  Jennifer Martinez,et al.  Rubicon: LC3‐associated phagocytosis and beyond , 2018, The FEBS journal.

[16]  K. Sleegers,et al.  An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer’s disease , 2018, Acta Neuropathologica.

[17]  K. Xia,et al.  Identification of rare RTN3 variants in Alzheimer’s disease in Han Chinese , 2018, Human Genetics.

[18]  E. Calabrese,et al.  Immune and Imaging Correlates of Mild Cognitive Impairment Conversion to Alzheimer’s Disease , 2017, Scientific Reports.

[19]  J. Corey-Bloom,et al.  Beneficial effects of glatiramer acetate in Huntington’s disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms , 2017, Brain Research.

[20]  K. Schuurman,et al.  Staining of HLA-DR, Iba1 and CD68 in human microglia reveals partially overlapping expression depending on cellular morphology and pathology , 2017, Journal of Neuroimmunology.

[21]  M. Z. Cader,et al.  A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response , 2017, Stem cell reports.

[22]  Ronald C. Petersen,et al.  TYROBP genetic variants in early-onset Alzheimer's disease , 2016, Neurobiology of Aging.

[23]  K. Mayer-Barber,et al.  Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses , 2016, Cellular & Molecular Immunology.

[24]  C. Broeckhoven,et al.  Molecular genetics of early-onset Alzheimer's disease revisited , 2016, Alzheimer's & Dementia.

[25]  Giuliano Binetti,et al.  A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer’s disease , 2016, Acta Neuropathologica.

[26]  S. Gordon.  Phagocytosis: An Immunobiologic Process. , 2016, Immunity.

[27]  A. Nimmerjahn,et al.  TAM receptors regulate multiple features of microglial physiology , 2016, Nature.

[28]  E. Chang,et al.  Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse , 2016, Neuron.

[29]  P. Deyn,et al.  A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42 , 2015, Alzheimer's & Dementia.

[30]  M. Guillot-Sestier,et al.  Innate Immunity Fights Alzheimer's Disease , 2015, Trends in Neurosciences.

[31]  W. V. van Gool,et al.  Systemic inflammation and microglial activation: systematic review of animal experiments , 2015, Journal of Neuroinflammation.

[32]  Toshiyuki Shimizu,et al.  Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9 , 2015, Nature.

[33]  P. Deyn,et al.  Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia , 2014, Neurobiology of Aging.

[34]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[35]  C. Cunningham,et al.  A Systematic Analysis of the Peripheral and CNS Effects of Systemic LPS, IL-1Β, TNF-α and IL-6 Challenges in C57BL/6 Mice , 2013, PloS one.

[36]  Douglas Golenbock,et al.  The history of Toll-like receptors — redefining innate immunity , 2013, Nature Reviews Immunology.

[37]  B Croisile,et al.  High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease , 2012, Molecular Psychiatry.

[38]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[39]  P. D. Rijk,et al.  Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing , 2011, Nature Biotechnology.

[40]  R. Hohlfeld,et al.  Glatiramer Acetate in the Treatment of Multiple Sclerosis , 2011, CNS drugs.

[41]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[42]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[43]  Pedro Romero,et al.  Type I interferon inhibits interleukin-1 production and inflammasome activation. , 2011, Immunity.

[44]  M. Tommasino,et al.  EBV Latent Membrane Protein 1 Is a Negative Regulator of TLR9 , 2010, The Journal of Immunology.

[45]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[46]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[47]  B. Mishra,et al.  Expression and distribution of Toll‐like receptors in the brain during murine neurocysticercosis , 2006, Journal of Neuroimmunology.

[48]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[49]  J. Wiltfang,et al.  Amyloid beta peptide 1–40 enhances the action of Toll‐like receptor‐2 and ‐4 agonists but antagonizes Toll‐like receptor‐9‐induced inflammation in primary mouse microglial cell cultures , 2005, Journal of neurochemistry.

[50]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[51]  H. Wagner.  The immunobiology of the TLR9 subfamily. , 2004, Trends in immunology.

[52]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[53]  T. Giese,et al.  Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides1 , 2002, The Journal of Immunology.

[54]  J C Murray,et al.  Pediatrics and , 1998 .

[55]  R. Liblau,et al.  Antagonistic Action of IFN-β and IFN-γ on High Affinity Fcγ Receptor Expression in Healthy Controls and Multiple Sclerosis Patients , 1998, The Journal of Immunology.

[56]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[57]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[58]  H. Braak,et al.  Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.

[59]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[60]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[61]  A. Casellas,et al.  Anti-inflammatory action of type I interferons deduced from mice expressing interferon β , 2000, Gene Therapy.